Canada markets close in 3 hours 48 minutes

  • S&P/TSX

    19,608.37
    -192.24 (-0.97%)
     

  • S&P 500

    4,291.31
    -46.13 (-1.06%)
     

  • DOW

    33,730.83
    -276.05 (-0.81%)
     

  • CAD/USD

    0.7402
    -0.0031 (-0.42%)
     

  • CRUDE OIL

    90.54
    +0.86 (+0.96%)
     

  • Bitcoin CAD

    35,335.86
    -172.77 (-0.49%)
     

  • CMC Crypto 200

    559.71
    -4.11 (-0.73%)
     

  • GOLD FUTURES

    1,920.40
    -16.20 (-0.84%)
     

  • RUSSELL 2000

    1,774.17
    -10.07 (-0.56%)
     

  • 10-Yr Bond

    4.5440
    +0.0020 (+0.04%)
     

  • NASDAQ

    13,111.21
    -160.11 (-1.21%)
     

  • VOLATILITY

    18.71
    +1.81 (+10.71%)
     

  • FTSE

    7,625.72
    +1.73 (+0.02%)
     

  • NIKKEI 225

    32,315.05
    -363.57 (-1.11%)
     

  • CAD/EUR

    0.6998
    -0.0017 (-0.24%)
     
MARKETS LIVE BLOG:

STOCKS SLIDE ON FED FALLOUT, SHUTDOWN WORRIES

U.S. consumer confidence declines for second consecutive month

Celldex to Participate in Upcoming November Investor Conferences

Celldex Therapeutics, Inc.
·1 min read
Celldex Therapeutics, Inc.
Celldex Therapeutics, Inc.

HAMPTON, N.J., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that management will participate in fireside chats at the following investor conferences in November:

  • Guggenheim 4th Annual Immunology and Neurology Conference on Monday, November 14, 2022 at 2:10 p.m. ET

  • Jefferies London Healthcare Conference on Wednesday, November 16, 2022 at 4:45 a.m. ET / 9:45 a.m. GMT

  • Evercore ISI 5th Annual HealthCONx Conference on Wednesday, November 30, 2022 at 4:45 p.m. ET

Webcasts of the presentations will be available on the "Events & Presentations" of the "Investors & Media" section of the Celldex website. Replays will be available for 30 days following the events.

About Celldex Therapeutics, Inc.
Celldex is a clinical stage biotechnology company dedicated to developing monoclonal and bispecific antibodies that address devastating diseases for which available treatments are inadequate. Our pipeline includes antibody-based therapeutics which have the ability to engage the human immune system and/or directly affect critical pathways to improve the lives of patients with inflammatory diseases and many forms of cancer. Visit www.celldex.com.

Company Contact
Sarah Cavanaugh
Senior Vice President, Corporate Affairs & Administration
(508) 864-8337
scavanaugh@celldex.com

Patrick Till
Meru Advisors
(484) 788-8560
ptill@meruadvisors.com